medigraphic.com
SPANISH

Cirugía Cardiaca en México

ISSN 2448-5640 (Print)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2020, Number 2

<< Back Next >>

Cir Card Mex 2020; 5 (2)

The Zero-Tolerance Approach to Standard AVR

Antunes MJ
Full text How to cite this article

Language: English
References: 14
Page: 34-37
PDF size: 217.12 Kb.


Key words:

Aortic valve, Aortic valve stenosis, Cardiac surgery, procedures, TAVI.

ABSTRACT

Conventionally, aortic valve stenosis (AS) is treated by surgical replacement of the valve (AVR), a very standardized and usually simple procedure that, however, still carries a significant perioperative mortality and morbidity, besides being associated to the late complications of the prostheses used. This procedure has been challenged by the recent introduction of percutaneous aortic valve implantation (TAVI), allegedly with better periprocedural results and, at least, similar longterm outcomes. Indeed, some believe that it will result in the demise of the surgical procedure.
In this text, I intend to demonstrate that we can obtain much better results with AVR than our cardiologists and ourselves believe. Using the Six-sigma (6-σ) developed by the industry that assures that 99.99966% of the products manufactured are statistically expected to be free of defects (3.4 defective parts/million). I believe that this concept is applicable to surgery. Indeed, some reference surgical centers now routinely have perioperative mortalities for AVR lower than 1%. Several risk factors for death and other complications have been identified that can be modified pre-operatively, leading to lower mortality and morbidity rates. Also, technical aspects of the procedure can be adjusted or modified with the same goal. Finally, the Heart Team and of the surgical staff, medical and nursing, play an important role in the success of the surgery, which, in my view, will still be part of our surgical armamentarium for the foreseeable future.


REFERENCES

  1. Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for the managementof valvular heart disease. Eur J Cardiothorac Surg 2017;52:616-64.

  2. Antunes MJ. Percutaneous aortic valve implantation. The demise of classical aorticvalve replacement? Eur Heart J 2008;29:1339-41.

  3. Osswald BR, Gegouskov V, Badowski-Zyla D, et al. Overestimation of aorticvalve replacement risk by EuroSCORE. Implications for percutaneous valve replacement.Eur Heart J 2008;3:74-80.

  4. Barreto-Filho JA, Wang Y, Dodson JA, et al. Trends in aortic valve replacementfor elderly patients in the United States, 1999-2011. JAMA 2013;310:2078-85.

  5. Jeffrey P. Jacobs JP, Shahian DM, D'Agostino RS, et al. The Society ofThoracic Surgeons National Database 2018 Annual Report. Ann ThoracSurg2018;106:1603–11.

  6. Paupério GS, Pinto CS, Antunes PE, Antunes MJ. Aortic valve surgery in patientswho had undergone surgical myocardial revascularization previously. Eur J CardiothoracSurg 2012;42:826-30.

  7. Eggebrecht H, Mehta RH. Transcatheter aortic valve implantation (TAVI) in Germany:more than 100,000 procedures and now the standard of care for the elderly.EuroIntervention. 2019;14:e1549-52.

  8. Thakar CV, Worley S, Arrigain S, Yared JP, Paganini EP. Influence of renal dysfunctionon mortality after cardiac surgery: modifying effect of preoperative renalfunction. Kidney Int 2005;67:1112-9.

  9. Antunes PE, Prieto D, Ferrão de Oliveira J, Antunes MJ. Renal dysfunction aftermyocardial revascularization. Eur J Cardiothorac Surg. 2004;25:597-604.

  10. Scott DA, Tung HM, Slater R. Perioperative Hemoglobin Trajectory in Adult CardiacSurgical Patients. J Extra Corpor Technol 2015;47:167-73.

  11. Sanetra K, Gerber W, Shrestha R, et al. The del Nido versus cold blood cardioplegiain aortic valve replacement: A randomized trial. J Thorac Cardiovasc Surg2019. pii: S0022-5223(19)31321-2. doi: 10.1016/j.jtcvs.2019.05.083.

  12. Correia PM, Coutinho GF, Branco C, Antunes MJ. Long-term follow-up of patientsundergoing aortic root enlargement for insertion of a larger prosthesis. Eur JCardiothorac Surg 2016;50:82-8.

  13. Kinsley RH, Antunes MJ, McKibbin JK. Enlargement of the narrow aortic rootand oblique insertion of a St. Jude prosthesis. Br Heart J 1983;50:330-2.

  14. Tabata M, Shibayama K, Watanabe H, Sato Y, Fukui T, Takanashi S. Simple interruptedsuturing increases valve performance after aortic valve replacement with asmall supra-annular bioprosthesis. J Thorac Cardiovasc Surg 2014;147:321-5.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Cir Card Mex. 2020;5